A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects
Completed · Phase 1 · Has a placebo group
Conditions studied: Type 2 Diabetes Mellitus
In brief
This study represents the first administration of GSK376501 in humans and the goal is to evaluate its initial safety and tolerability. The way the human body processes GSK376501 will also be determined.
Key facts
- Study ID
- NCT00404963
- Run by
- GlaxoSmithKline
- People needed
- 72
- Starts
- 2006-10-01
- Expected to finish
- 2007-05-01
- Last updated by the study team
- 2017-01-19
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- GSK Investigational Site — Evansville, Indiana, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.